ARCHIVES

Adverse data from cancer prevention trial makes Merck withdraw Vioxx from market. Researchers discuss implications for other cancer prevention trials.

This article is from The Cancer Letter archive.

Vol. 30 No. 39 | October 15, 2004

Download PDF Visit The Full Archive

Related Articles

New Community Control Program May Be Developed

October 24, 1975

Obesity, Faster Weight Gain, Linked To Poor Prognosis

October 28, 2005

NCI To Fund Two Construction Grants With 42 Million From Special NIH Fund

March 2, 1990

New Food Technology Could Lower Cancer Risk, Greenwald Says; Nutrition Lab Needed

January 27, 1989

Herceptin Regimen Minus Adriamycin Increases Survival With Less Toxicity

October 28, 2011

Gene Therapy Hyped By Scientists, Panel Tells NIH; Emphasis Must Be Basic Research

December 15, 1995